Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 3/20 | 0.37 |
| ▸ | MC5R | P33032 | 3/20 | 0.37 |
| ▸ | MC3R | P41968 | 3/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417987 | 0.89 | CCR6 (0.46) | CCR6PAX8CCKBRALDH1A1MAPK1 | |
| SCHEMBL417677 | 0.89 | ALDH1A1 (0.40) | CCR6PAX8CCKBRALDH1A1MAPK1 | |
| SCHEMBL759516 | 0.82 | CCR6 (0.66) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7535687 | 0.81 | CCR6 (0.64) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL415523 | 0.80 | CCR6 (0.54) | CCR6PAX8MC4RMC5RMC3R | |
| SCHEMBL417676 | 0.78 | CCR6 (0.52) | CCR6PAX8MC4RMC5RMC3R | |
| SCHEMBL15355992 | 0.77 | CCR6 (0.59) | CCR6PAX8CCKBRALDH1A1MAPK1 | |
| SCHEMBL2076709 | 0.77 | CCR6 (0.59) | CCR6PAX8MC4RMC5RMC3R | |
| SCHEMBL10181395 | 0.76 | CCR6 (0.61) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL17377997 | 0.76 | CCR6 (0.61) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664409-B2 | Process for the preparation of (poly) aminoalkylaminoacetamide derivatives of epipodophyllotoxin useful for their applications in therapeutics as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-03-04 | — | — | US | disclosed |
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-01-26 | — | — | US | disclosed |
| CN-1946727-B | (Poly) aminoacetamide derivatives of epipodophyllotoxin, their process of preparation and their applications in therapeutics as anticancer agents | PF MEDICAMENT | 2010-08-11 | — | — | CN | disclosed |
| CN-1946727-A | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | PF MEDICAMENT (FR) | 2007-04-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PTMA, NPEPPS, DNPEP | CCR6 3824/4885PAX8 2180/4885CCKBR 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.